FDA slaps Zhuhai United Laboratories with warning letter for sterile injectables plant

The FDA cited Zhuhai United Laboratories' drug manufacturing facility in Zhuhai, China, with a warning after finding aseptic processing issues. (Pixabay/qimono)

A Chinese CMO that produces sterile drugs has been slapped with an FDA warning letter after a preapproval inspection found serious issues with its aseptic processes.

The FDA issued the letter to Zhuhai United Laboratories' drug manufacturing facility in Zhuhai, China, after an inspection in September 2017. The plant makes both sterile injectables and other APIs and intermediates.

Among other issues, the FDA said it found “examples of incomplete data relating to the sterile manufacturing operations evaluated as part of our pre-approval inspection.” For instance, the company failed to maintain electronic data documenting decontamination cycles for the grade A area of the workshop where it aseptically manufactures sterile powders. Inspectors found that Zhuhai United Laboratories overwrote the electronic data and kept only a cursory written record.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It also did not assure reliability of electronic data for monitoring nonviable particles in manufacturing areas. Investigators observed that the company disabled the electronic audit trail function for the nonviable particle monitoring system for several workshops on at least two occasions in August 2017 when a sterile API was manufactured. Also, data files containing particle counts had been modified with no indication of who made the changes or what was modified.

On the solid dose side, inspectors found that the company lacked adequate procedures for its out-of-specification investigations and lacked scientific justification for its invalidated OOS results.

The agency gave Zhuhai United a long list of responses and explanations it wants and strongly suggested the company hire an outside consultant who can help it figure out how to meet cGMP standards.

Suggested Articles

Thermo Fisher Scientific's pharma services group is establishing itself as a gene therapy manufacturer with a $1.7 billion cash deal for Brammer Bio.

Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.